After making its debut on the ASX in April, biotech company Microba Life Sciences (ASX: MAP) has wasted little time delivering on its IPO prospectus promise to partner with a fast-growing and innovative Australian consumer-led healthcare business.
The Brisbane-based business, which looks to improve human health through precision microbiome science, has signed a strategic three-year agreement with digital healthcare start-up Midnight Health to deliver personalised health services to the Australian market.
Comments